Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225).
Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S. and international clinical trials. Actimab-A is an Ac-225-based radiotherapy agent that is directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia and other myeloid indications, according to Eckert & Ziegler.
As AuntMinnie.com has reported, newer cancer treatments that use alpha-emitters such as Ac-225 are in development worldwide. Demand for Ac-225 is driven in part by the rapid development of theranostic “pairs” used in imaging and therapy.